ERICAN NATUROPATHIC RESEARCH INSTITUTE

NATUROPATHIC ONCOLOGY RESEARCH INSTITUTE

Interim address:

1250 E. Baseline Rd., Suite 205

Tempe, AZ  85283

Tel: 480-839-2800

  JOINT MEETING OF THE

AMERICAN NATUROPATHIC RESEARCH INSTITUTE (ANRI)

 AND THE

NATUROPATHIC ONCOLOGY RESEARCH INSTITUTE (NORI)

 AND THE

INTERNATIONAL NATUROPATHIC CLINICAL RESEARCH INSTITUTE

AND THE

INSTITUTIONAL REVIEW BOARD (IRB)

May 10, 2019

MINUTES AND MEETING NOTES

 In accordance with the requirements of the United States Code of Federal Regulations, Title 21, Chapter 1, Subchapter A, Part 56, the thirty-eighth regular quarterly meeting of the American Naturopathic Research Institute (ANRI) and the Naturopathic Oncology Research Institute (NORI) and the International Naturopathic Clinical Research Institute (INCRI) and the Institutional Review Board (IRB) was called to order at 12:00 p.m., May 10, 2019 at 1250 E. Baseline Rd., Suite 205, meeting in Suite 203, Tempe, AZ  85283.

MEMBERS AND GUESTS

11 members and guests were in attendance.  This included 7 physicians and 4 non-physicians,

The meeting was called to order at 12:00 pm. 

OUTREACH BEYOND OUR IRB

The question was raised if we should ever reach out to other physicians who are doing unusual or groundbreaking work in their own clinics.  Pros and cons of doing this were discussed.

REGISTRATION OF IRBS WITH FDA AND OHRP

Clinicaltrials.org can show the IRBs that are registered.

We are still registering all IRBs presented and approved by us, and with both FDA and OHRP, pursuant to a vote of a long ago meeting that we do that.  We discussed our understanding of the Code of Federal Regulations regarding requirements for IRBs.

“DRUGS” VS “BIOLOGICS”

The question came up about how we register our studies on the OHRP/FDA website.  You are forced to choose between “drug” and “biologic” in order to proceed.  We discussed verbatim FDA definitions of “drug” vs “biologic,” the applicability to the studies that we review, and the ramifications of each.

A SPECIFIC STUDY

We discussed procedures regarding a study that we have approved.

CAUTION ON CERTAIN FOODS IN A PATIENT WITH HIGH IRON

A patient came in with high iron, who had been eating certain foods. We discussed the clinical implications.

GRAND ROUNDS

A lymphoma patient was mentioned.

Another case:  Patient with family devastated from the cancer and the medical bankruptcy that it inflicts.  Oncology team could not / would not comprehend the statement, “I don’t want chemo.”

NIH site has this stat:  Greater than 90% of patients are not expected to survive their cancer treatments.

Prostate cancer insight: We discussed viral contribution to this disease.

Hospice patient heard about natural treatments, and a year later was walking again, and later playing golf again. Reversed cancer and fibrosis.  However, the family was restless and on an agenda, and talked him into getting chemo, and he then died right after chemo.

We discussed a case of Lyme.

We discussed mycoplasma, its epidemiology and its treatments. 

Somebody asked about the wacko in Germany.  Cluster B personality disorder is a likely problem there.  She also now seems to have a vaccine-injured child, from her recent tweets, after having criticized vaccine safety advocates.  Relentless screaming instead of crying is pathognomonic for vaccine injury and/or brain inflammation in an infant. 

PRELIMINARY REVIEW OF NEW RESEARCH

One doctor is working up a protocol for new research.  This was presented as a preliminary idea for review.  The group asked questions and made suggestions for this research.  A formal proposal will be made in the future, but not today.

RECENT FDA MOVES TO ELIMINATE NATURAL SUBSTANCES AVAILABLE FOR USE

The AZNMA legislative committee is fighting the FDA on this and there are other organizations as well.  They want more signatories on a petition to the FDA.  They want organizations to sign.

The message of the petition is:  We object to the FDA’s unilateral banning of these medications without due process and review.

We voted and unanimously agreed to sign this as “ANRI / NORI,” and that the President of ANRI / NORI should be the one who signs.

NEXT MEETING

We will next meet on Friday, August 9, 2019, the usual time and place.